CSL (ASX:CSL) Issuance of Debt: A$587 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CSL CSL Ltd ASX:CSL
78 GF Score
Price A$121.34
GF Value A$286.91
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Issuance of Debt?

CSL ASX:CSL -1.26% 78 Issuance of Debt is A$587 Mil as of Dec. 2025. GuruFocus rates ASX:CSL with a GF Score™ of 78/100 and a GF Value™ of A$286.91 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL's Issuance of Debt for the six months ended in Dec. 2025 was A$587 Mil.

CSL's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was A$587 Mil.

CSL Issuance of Debt Historical Data

* Premium members only.

The historical data trend for CSL's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Issuance of Debt Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.62 5,823.91 3,783.11 3,099.35 148.99

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.41 1,184.74 1,905.09 0.00 586.95
ASX:CSL
78GF Score
CSL Ltd ASX:CSL
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$587 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of A$587 Mil mean?
CSL (ASX:CSL) has a Issuance of Debt of A$587 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on CSL and its competitors.
Is CSL's Issuance of Debt too high?
CSL's current Issuance of Debt is A$587 Mil. Overall, CSL has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Issuance of Debt compare to VRTX and REGN?
CSL's Issuance of Debt of A$587 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on CSL and its competitors. CSL's current Issuance of Debt is A$587 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (ASX:CSL) is currently considered Significantly Undervalued. The stock's GF Value™ is A$286.91, compared to a current price of A$121.34 — trading 57.7% below its estimated fair value. The current Issuance of Debt is A$587 Mil. CSL's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For CSL (ASX:CSL), the current Issuance of Debt is A$587 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (ASX:CSL) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of A$121.34 is trading 57.7% below its estimated GF Value™ of A$286.91. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for ASX:CSL:

  • Issuance of Debt: A$587 Mil
  • GF Value™: A$286.91 vs. price of A$121.34 (57.7% below fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the ASX:CSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
78GF Score

Get the complete analysis for ASX:CSL

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$121.34
Price
A$286.91
GF Value